EN IT

Oral Presentations

updated 12.12.2017

72. Fassina G. Biomarkers development for early detection of cancer: reducing the burden of cancer in the ageing society. Smart Specialization Strategy in the Field of Biotechnologies in Europe: A Challenge for CEE Region. Bratislava, Slovak Republic. 2017.
71. Fassina G. Hepa-IC: Discovery of a novel biomarker for liver diseases. Oman Health Expo. Muscat, Oman. 2015.
70. Fassina G. Novel biomarkers in personalized oncology. BioKorea 2015. Seoul, Korea. 2015.
69. Fassina G. Innovation in the field of diagnostics for healthcare: is innovation worth for improving health care or is it only an additional cost?. Trans2Care 2nd Spring Meeting. Venice, Italy. 2013.
68. Fassina G. Reducing the burden of cancer in the ageing society. World Academy of Art and Science Forum on "Science and Technology: Impact on Society and Economy". Trieste, Italy. 2013.
67. Fassina G, Gallotta A. Optical biochips for cancer early detection. Nanotec 2013. Venice, Italy. 2013.
66. Fassina G, Gallotta A. Optical biochips for biomarker-IgM complexes codetermination in hepatocellular carcinoma. 1° Convegno Nazionale Sensori. Rome, Italy. 2012.
65. Buccione D, Fatti G, Gallotta A, Loggi E, Di Donato R, Testa L, Saitta C, Santi V, Di Micoli A, Fazio V, Picciotto A, Biasiolo A, Pontisso P, Raimondo G, Trevisani F. SCCA-IgM as a marker of hepatocellular carcinoma (HCC) in patients with liver cirrhosis. XX Conv. Int. Attualità e Prospettive in Epatologia. Padua, Italy. 2010.
64. Fassina G. Biochips for Hepatocellular Carcinoma. Alp Nano Bio International School. Vipiteno, Italy. 2010.
63. Verna M, Pengo P, Gallotta A, Zani D, Costa S, Leon A, Gion M, Fassina G, Beneduce L. Improved detection of low grade prostate cancer by PSA-IgM assessment. XX Cogresso Nazionale Società Italiana di Urologia Oncologica (SIUrO). Rome, Italy. 2010.
62. Zani D, Costa S, Pettenò A, Simeone C, Cosciani Cunico S, Leon AE, Gion M, Fassina G, Beneduce L. Combined role of serum assays of PSA-IgM and PSA for the diagnosis of prostate cancer. XX Congresso Nazionale Società Italiana di Urologia Oncologica (SIUrO). Rome, Italy. 2010.
61. Beneduce L. Gli immunocomplessi IgM: una nuova classe di biomarcatori tumorali. Applicazione delle nanotecnologie nel management del cancro. Venice, Italy. 2009.
60. Bucca E, Beneduce L, Leon A, Fabricio A, Michilin S, Bellucco C, Rizzo A, Zuin J, Veggiani G, Fassina G, Gion M. The simultaneous assessment of circulating levels of free CA15.3 and CA15.3-IgM for improving breast cancer detection. 2° Evento Nazionale Congiunto SIBioC -SIMeL. Naples, Italy. 2009.
59. Fassina G. Biochips for cancer early detection. Alp Nano Bio International School. Vipiteno, Italy. 2009.
58. Fassina G. Il ruolo della industria del diagnostico nel trasferimento tecnologico degli IVD Biomarcatori in oncologia. salute@venezia. Venice, Italy. 2009.
57. Fassina G. Merging nanotechnology and biotechnology:a new frontier in cancer detection. Applicazione delle nanotecnologie nel management del cancro. Venice, Italy. 2009.
56. Fassina G. Multimarker biochip for the diagnosis of hepatocellular carcinoma. International Congress, Biochip Development for Cancer Diagnosis. Venice, Italy. 2009.
55. Fassina G. XEPTAGEN: Company profile. Research and Innovation Forum. Padua Italy. 2009.
54. Gallotta A. Biosensoristica in campo clinico: rivelazione di marcatori oncologici IgM complessati con metodi optoelettronici. Seminario al Corso Integrato di Nanotecnologie e Biosensori. University of Bologna, Italy. 2009.
53. Gallotta A. Dispositivi optoelettronici per l'analisi di immunocomplessi IgM per la diagnosi tumorale. Applicazione delle nanotecnologie nel management del cancro. Venice, Italy. 2009.
52. Quarta S, Vidalino L, Turato C, Ruvoletto M, Calabrese F, Fassina G, Gatta A, Pontisso P. SERPINB3 induces epithelial mesenchymal transition. Monothematic Conference of the Italian Association of the Study of the Liver (AISF). Messina, Italy. 2009.
51. Turato C, Calabrese F, Biasiolo A, Quarta S, Ruvoletto M, Tono N, Franzosi L, Paccagnella D, Fassina G, Gatta A, Pontisso P. SERPINB3 and TGF-beta1 in chronic liver disease. Annual Meeting Italian Association for the Study of the Liver (AISF). Rome, Italy. 2009.
50. Zani D, Costa S, Gatti L, Pesenti N, Pettenò A, Zambolin T, Simeone C, Cosciani Cunico S, Leon A, Zuin J, Fassina G, Beneduce L. Studio dell'associazione PSA-IgM e PSA totale per la diagnosi del carcinoma prostatico. 82° Congresso SIU. Rimini, Italy. 2009.
49. Bucca E, Beneduce L, Leon A, Fabricio A, Michilin S, Steffan A, Durante C, Bellucco C, Rizzo A, Berlanda G, Perasole A, Zampieri F, Zuin J, Fassina G, Gion M. The combination of free CA15.3 and CA15.3-IgM complexes enhances discrimination between healthy subjects and breast cancer patients. Third EORTC PathoBiology Group Annual Meeting. Milan, Italy. 2008.
48. Fassina G. Biochips for cancer early detection. Italy-USA Bio-Nano Business forum 2008. Boston, USA. 2008.
47. Fassina G. Cancer polymarkers biochip. Nanotec 2008. Venice, Italy. 2008.
46. Fassina G. Combinatorial approaches in cancer early detection. Drug Design and Discovery for Developing Countries. Trieste, Italy. 2008.
45. Fassina G. XEPTAGEN: Company profile. Research and Innovation Forum. Padua, Italy. 2008.
44. Gallotta A. Optical biochip for the assessment of immune complexes for cancer diagnosis. Perspectives in Biochip Development. Pisa, Italy. 2008.
43. Zani D, Pezzoni G, Pettenò A, Simeoni C, Cosciani Cunico S, Beneduce L, Gallotta A, Fassina G. Validazione dell'uso di PSA e immunocomplessi PSA-IgM nella diagnostica della neoplasia prostatica organoconfinata. Congresso SIU. Rome, Italy. 2008.
42. Fassina G. Biochips in diagnostica oncologica. Impatto delle Micro- e Nano-tecnologie sui Bioprocessi, RichMac. Milan, Italy. 2007.
41. Fassina G. XEPTAGEN Company Profile 2007. Annual BioPartnering North America. Vancouver, Canada. 2007.
40. Fulgenzi C. Opportunities at XEPTAGEN 2007. College of Pharmacy, Unversity of Padua. Padua, Italy. 2007.
39. Fulgenzi C. XEPTAGEN 2007. Annual Assobiotec-Assobiomedica Encounter sponsored by Federchimica. Milan, Italy. 2007.
38. Vidalino L, Quarta S, Baesso I, Ruvoletto M, Frezzato F, Trentin L, Bernardinello E, Fassina G, Cavalletto L, Chemello L, Gatta A, Pontisso P. Squamous cell carcinoma antigen (SCCA) expression and CD27+ nemory B lymphocytes in patients with chronic hepatitis C. Annual Meeting Italian Association for the Study of the Liver (AISF). Rome, Italy. 2007.
37. Villano G, Vidalino L, Ruvoletto M, Dall'Olmo L, Arben D, Giacometti C, Biasiolo A, Quarta S, Beneduce L, Calabrese F, Fassina G, Gatta A, Pontisso P. Squamous cell carcinoma Antigen (SCCA) improves liver regeneration in a transgenic mouse model. Annual Meeting Italian Association for the Study of the Liver (AISF). Rome, Italy. 2007.
36. Beneduce L, Marino M, Gallotta A, Pesce G, Pontisso P, Fassina G. A new class of biomarkers for hepatocellular carcinoma: IgM immune complexes. International Symposium on Viral Hepatitis and Liver Disease. Paris, France. 2006.
35. Fassina G. Cancer biochips. Cancer Nanotech Conference. Paris, France. 2006.
34. Prayer-Galetti T, Beneduce L, Giustinian AMG, Gallotta A, Fracalanza S, Betto G, Artibani W, Pagano F, Fassina G. PSA-IgM complessato (IC) un nuovo biomarcatore per il carcinoma della prostata. Congresso Nazionale (SIU). Bologna, Italy. 2006.
33. Quarta S, Caberlotto C, Beneduce L, Marino M, Fassina G, Tono N, Cavalletto L, Chemello L, Gatta A, Pontisso P. Monitoring SCCA-IgM complex predicts HCC development in cirrhotic patients. International Symposium on Viral Hepatitis and Liver Disease. Paris, France. 2006.
32. Vidalino L, Quarta S, Baesso I, Cavasin L, Bernardinello E, Ruvoletto M, Frezzato F, Trentin L, Fassina G, Cavalletto L, Chemello L, Gatta A, Pontisso P. Deregulation of squamous cell carcinoma antigen (SCCA) expression in B Lymphocytes in patients with chronic Hepatitis C. International Symposium on Viral Hepatitis and Liver Disease. Paris, France. 2006.
31. Beneduce L, Castaldi F, Marino M, Quarta S, Ruvoletto M, Pontisso P, Fassina G. Circulating squamous cell carcinoma antigen-IgM complexes as novel biomarkers for hepatocellular carcinoma. Annual Meeting Italian Association for the Study of the Liver (AISF). Rome, Italy. 2004.
30. Fassina G. Combinatorial proteomic: applications in Oncology. Biophysics School. Bressanone. 2004.
29. Fassina G. Combinatorial technologies in biotechnology. Controlled Release Society Workshop, University of Padua. Padua, Italy. 2004.
28. Fassina G. Combinatorial technologies in biotechnology. UNIDO Workshop on Combinatorial Chemistry and Combinatorial Technologies. Moscow, Russia. 2004.
27. Fassina G. Nanosized cancer polymarkers biochip. Micro- and Nanotechnologies in the life sciences. Zurich, Swiss. 2004.
26. Fassina G. Novel serum biomarkers for hepatocellular carcinoma. Endocrinology and Experimental Oncology Institute 'G. Salvatore', National Research Council. Naples, Italy. 2004.
25. Fassina G. The biotech bet. GEAR, University of Naples. Naples, Italy. 2004.
24. Fassina G. XEPTAGEN: company profile BioContact. Quèbec 2004. Montreal, Canada. 2004.
23. Marino M. In vitro diagnostic medical devices development: industrial approach. Department of Biotechnology, University of Caserta. Caserta, Italy. 2004.
22. Pontisso P, Fassina G, Quarta S, Ruvoletto M, Tono N, Castaldi F, Nigro A, Marino M, Beneduce L, Gatta A. Nanotecnologie nella diagnostica dell'epatocarcinoma. 14° Conv. Int. Attualità e Prospettive in Epatologia. Padua, Italy. 2004.
21. Fassina G. Biotechnologies & nanotechnologies: new frontiers for new drugs development. VE.GA Scientific Park. Marghera, Italy. 2003.
20. Fassina G. Combinatorial Proteomic and identification of novel tumoral biomarkers. BIONOVA 2003. Padua, Italy. 2003.
19. Fassina G. Combinatorial technologies. Department of Biotechnology, University of Caserta. Caserta, Italy. 2003.
18. Fassina G. Factors affecting Biotech Development. WEBB IT. Padua, Italy. 2003.
17. Fassina G. Intellectual property management. CCIAA Naples. Naples, Italy. 2003.
16. Fassina G. Merging biotechnologies and nanotechnologies: a frontier in oncology and a business opportunity. EuroNanoForum. Trieste, Italy. 2003.
15. Fassina G. Micro- and nanofabricated sensors for the detection of DNA and protein. University of Bologna. Bologna, Italy. 2003.
14. Fassina G. Molecular design and combinatorial chemistry and promotion of related projects. ICS UNIDO, Combinatorial Chemistry and Technologies Workshop. Trieste, Italy. 2003.
13. Fassina G. Trends and applications of combinatorial chemistry and technology. ICS UNIDO, Combinatorial Chemistry and Technologies Workshop. Trieste, Italy. 2003.
12. Palomba D. Combinatorial Chemistry : an overview. Department of Biotechnology, University of Caserta. Caserta, Italy. 2003.
11. Palomba D. Proteomica Combinatoriale: identificazione di nuovi targets molecolari in oncologia. Menarini Ricerche SpA. Pomezia, Italy. 2003.
10. Pontisso P, Calabrese F, Benvegnù L, Belluco C, Ruvoletto M, Marino M, De Falco S, Valente M, Nitti D, Alberti A, Gatta A, Fassina G. Squamous cell carcinoma antigen variants overexpression in hepatocellular carcinoma. 11th International Symposium on Viral Hepatitis & Liver Disease. Sydney, Australia. 2003.
9. Quarta S, Vidalino L, Borgo R, Beneduce L, Villano G, Beneduce L, Marino M, Fassina G, Gatta A, Pontisso P. SCCA1 activates cell proliferation in HepG2 cells: possible role in HCC development. National Congress of the Italian Society of Virology (SIV). Cortona, Italy. 2003.
8. Quarta S, Vidalino L, Ruvoletto M, Tono N, Villano G, Beneduce L, Fassina G, Gatta A, Pontisso P. Attività biologica della serpina SCCA1 nell'epatocarcinoma. Convegno Internazionale Attualità e Prospettive in Epatologia. Padua, Italy. 2003.
7. Sannino M. Strategies for adding value to a biotech company: the XEPTAGEN approach. BIONOVA 2003. Padua, Italy. 2003.
6. Calabrese F, Belluco C, Benvegnù L, Ruvoletto M, Valente M, Marino M, Nitti D, Alberti A, Gatta A, Fassina G, Pontisso P. High expression of serine protease inhibitor (SCCA) variants in hepatocarcinoma. Annual Meeting Italian Association for the Study of the Liver (AISF). Rome, Italy. 2002.
5. Fassina G. Combinatorial proteomic and biomarker identification in oncology. Italo-Japanese bilateral seminar, Toward the post-sequencing era: new opportunities for scientific cooperation between Italy and Japan in basic and applied cancer research. Tokyo, Japan. 2002.
4. Fassina G. Combinatorial Technologies in Drug Discovery. University of Trieste. Trieste, Italy. 2002.
3. Fassina G. Trends and applications of combinatorial chemistry and combinatorial technologies. ICS UNIDO, Combinatorial Chemistry and Technologies Workshop. Sao Carlos, Brazil. 2002.
2. Fassina G, Marino M, Ruvoletto M. SCCA and liver diseases. International Symposium on the Biology, Structure and Function of Serpins. Chicago, USA. 2002.
1. Pontisso P, Calabrese F, Benvegnù L, Ruvoletto M, Bellucco C, Marino M, Ruvo M, Valente M, Giacometti C, Nitti D, Alberti A, Gatta A, Pontisso P, Fassina G. High espression of serine protease inhibitor (SCCA) variants in human hepatocarcinoma. European Meeting on Hepatocarcinogenesis: From Basic Science to Treatment. Cagliari, Itlay. 2001.